Chemical Nameavacopan
Dosage FormCapsule (oral; 10 mg)
Drug ClassReceptor antagonists
Approval Year2021


  • Indicated as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids. TAVNEOS does not eliminate glucocorticoid use
Last updated on 3/15/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Tavneos (avacopan) Prescribing Information.2021Thermo Fisher Scientific, Cincinnati, OH
Interventions for renal vasculitis in adults.2020Cochrane Database of Systematic Reviews
Document TitleYearSource
Assessment report: tavneos. 2022EMA